Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi’s sarcoma: a real-life study

References

• Parkin DM, Hämmerl L, Ferlay J, Kantelhardt EJ. Cancer in Africa 2018: The role of infections. Int J Cancer. 2020;146(8):2089–103. Epub 2019 Aug 2. PMID: 31254479.
   PubMed Web of Science ®Google Scholar
• Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495–e504. Epub 2017 Aug 10. PMID: 28803888; PMCID: PMC5669995.
   PubMed Web of Science ®Google Scholar
• Peters BS, Beck EJ, Coleman DG, Wadsworth MJ, McGuinness O, Harris JR, Pinching AJ. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. BMJ. 1991;302(6770):203–7.
   PubMedGoogle Scholar
• Lifson AR, Darrow WW, Hessol NA, O'Malley PM, Barnhart JL, Jaffe HW, Rutherford GW. Kaposi’s sarcoma in a cohort of homosexual men and bisexual men: epidemiology and analysis of cofactors. Am J Epidemiol. 1990;131(2):221–31.
   PubMed Web of Science ®Google Scholar
• Pria AD, Hayward K, Bower M. Do we still need chemotherapy for AIDS-associated Kaposi’s sarcoma? Expert Rev Anticancer Ther. 2013;13(2):203–9.
   PubMed Web of Science ®Google Scholar
• Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: Results of a randomized phase III clinical trial. JCO. 1998;16(7):2445–51.
   PubMed Web of Science ®Google Scholar
• Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol. 1996;36(1):55–63.
   PubMed Web of Science ®Google Scholar
• Osoba D, Northfelt DW, Budd DW, Himmelberger D. Effect of treatment on health related quality of life in acquired immunodeficiency syndrome (AIDS)- related Kaposi’s sarcoma: A randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest. 2001;19(6):573–80.
   PubMed Web of Science ®Google Scholar
• Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. JCO. 1998; 16(2):683–91.
   PubMed Web of Science ®Google Scholar
• Lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K, Mauss S, Rockstroh JK. Treatment of HIV-1-associated Kaposi’s sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection. 2005; 33(3):140–7.
   PubMed Web of Science ®Google Scholar
• Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15(9):3085–92. PMID: 9294471.
   PubMed Web of Science ®Google Scholar
• Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. JCO. 1989;7(9):1201–7.
   PubMed Web of Science ®Google Scholar
• Brambilla L, Romanelli A, Bellinvia M, Ferrucci S, Vinci M, Boneschi V, Miedico A, Tedeschi L. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br J Dermatol. 2008;158(6):1339–44. Epub 2008 Mar 20.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Polizzotto MN, Aleman K, Wyvill KM, Marshall V, Whitby D, Wang V, Pittaluga S, O’Mahony D, Steinberg SM, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124(24):3544–52. Epub 2014 Oct 20. PMID: 25331113; PMCID: PMC4256906.
   PubMed Web of Science ®Google Scholar
• Brambilla L, Bellinvia M, Tourlaki A, Scoppio B, Gaiani F, Boneschi V. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol. 2010;162(4):854–9. Epub 2009 Nov 25. Erratum in: Br J Dermatol. 2010 Apr;162(4):907-8. Dosage error in article text. PMID: 19995366.
   PubMed Web of Science ®Google Scholar
• Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS. 2008;22(8):937–45.
   PubMed Web of Science ®Google Scholar
• Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Mena M, et al. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era–the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of patients naive from antiretrovirals. JCO. 2003;21(15):2876–82.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Powles T, Bower M. AIDS-associated Kaposi’s sarcoma associated with a low viral load and a high CD4 cell count. AIDS. 2008;22(4):551–2.
   PubMed Web of Science ®Google Scholar
• Daly M-L, Fogo A, McDonald C, Morris-Jones R. Kaposi sarcoma: no longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm3 at presentation. Clin Exp Dermatol. 2014; 39(1):7–12.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, for the Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD, et al. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013;57(7):1038–47.
   PubMed Web of Science ®Google Scholar